他汀类药物的使用是否能降低肾移植人群中与皮质类固醇相关的骨坏死风险？
Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population?
作者信息
Ajmal Muhammad, Matas A J, Kuskowski Michael, Cheng Edward Y
机构信息
Department of Orthopaedic Surgery, Veterans Affairs Hospital, Vanderbilt University, 1310 24th Avenue South, Nashville, TN 37212, USA.
出版信息
Orthop Clin North Am. 2009 Apr;40(2):235-9. doi: 10.1016/j.ocl.2009.01.004.
Abstract
The relationship between corticosteroids and osteonecrosis is well known. Limited data suggest that statins modulate cholesterol metabolism and may protect against osteonecrosis. The authors analyzed their prospective renal transplant database to determine if statin usage reduces the incidence of corticosteroid-related osteonecrosis and identified 2,881 renal transplantation patients who met the entry criteria. Among 338 patients on statins, 15 (4.4%) developed osteonecrosis, versus 180 of 2,543 (7%) patients who were not on statins. Osteonecrosis-free survival was similar in patients with and without statin exposure.
摘要
皮质类固醇与骨坏死之间的关系已为人熟知。有限的数据表明，他汀类药物可调节胆固醇代谢，可能预防骨坏死。作者分析了他们的前瞻性肾移植数据库，以确定使用他汀类药物是否能降低皮质类固醇相关骨坏死的发生率，并确定了2881名符合入选标准的肾移植患者。在338名服用他汀类药物的患者中，15名（4.4%）发生了骨坏死，而在2543名未服用他汀类药物的患者中有180名（7%）发生了骨坏死。服用和未服用他汀类药物的患者无骨坏死生存率相似。
相似文献
1
Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population?他汀类药物的使用是否能降低肾移植人群中与皮质类固醇相关的骨坏死风险？
Orthop Clin North Am. 2009 Apr;40(2):235-9. doi: 10.1016/j.ocl.2009.01.004.
2
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].[肾衰竭患者使用他汀类药物：慢性肾病和肾移植患者的疗效、耐受性及处方指南]
Presse Med. 2006 Feb;35(2 Pt 1):219-29. doi: 10.1016/s0755-4982(06)74557-2.
3
Statin therapy decreases the risk of osteonecrosis in patients receiving steroids.他汀类药物治疗可降低接受类固醇治疗患者发生骨坏死的风险。
Clin Orthop Relat Res. 2001 May(386):173-8. doi: 10.1097/00003086-200105000-00022.
4
Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression.
Transplant Proc. 2002 Feb;34(1):398-400. doi: 10.1016/s0041-1345(01)02836-6.
5
HMG CoA reductase inhibitors (statins) for kidney transplant recipients.肾移植受者使用的HMG CoA还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2014 Jan 28;2014(1):CD005019. doi: 10.1002/14651858.CD005019.pub4.
6
Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents.他汀类药物治疗与儿童和青少年心脏移植后的预后改善无关。
J Heart Lung Transplant. 2016 Apr;35(4):457-65. doi: 10.1016/j.healun.2015.10.040. Epub 2015 Nov 22.
7
HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival.在接受他克莫司治疗的肾移植受者中，HMG-CoA 还原酶抑制剂：他汀类药物与改善患者或移植物存活率无关。
BMC Nephrol. 2010 Apr 1;11:5. doi: 10.1186/1471-2369-11-5.
8
HMG CoA reductase inhibitors (statins) for kidney transplant recipients.用于肾移植受者的HMG CoA还原酶抑制剂（他汀类药物）。
Cochrane Database Syst Rev. 2009 Apr 15(2):CD005019. doi: 10.1002/14651858.CD005019.pub3.
9
Tacrolimus may be associated with lower osteonecrosis rates after renal transplantation.他克莫司可能与肾移植后较低的骨坏死发生率相关。
Clin Orthop Relat Res. 2003 Oct(415):163-70. doi: 10.1097/01.blo.0000093908.26658.df.
10
Incidence and Risk Factors for Nontraumatic Osteonecrosis of the Femoral Head in Kidney Transplant Recipients: A Comparison of Two Eras (1985-2000 and 2001-2024).
Clin Transplant. 2025 Jun;39(6):e70198. doi: 10.1111/ctr.70198.
引用本文的文献
1
The Relationship Between Femoral Head Avascular Necrosis and Erectile Dysfunction: A Retrospective Case-Control Study Conducted in Türkiye.股骨头缺血性坏死与勃起功能障碍之间的关系：在土耳其进行的一项回顾性病例对照研究
J Clin Med. 2025 Apr 14;14(8):2674. doi: 10.3390/jcm14082674.
2
Hip joint-preserving strategies for treating osteonecrosis of the femoral head: From nonoperative to operative procedures.治疗股骨头坏死的髋关节保留策略：从非手术到手术方法
J Orthop Translat. 2025 Mar 19;51:256-277. doi: 10.1016/j.jot.2025.02.001. eCollection 2025 Mar.
3
Conservative Treatment in Avascular Necrosis of the Femoral Head: A Systematic Review.保守治疗股骨头缺血性坏死的系统评价。
Med Sci (Basel). 2024 Jul 2;12(3):32. doi: 10.3390/medsci12030032.
4
A Comparative Analysis of Osteochondritis Dissecans and Avascular Necrosis: A Comprehensive Review.剥脱性骨软骨炎与缺血性坏死的比较分析：综述
J Clin Med. 2024 Jan 4;13(1):287. doi: 10.3390/jcm13010287.
5
Updating Osteonecrosis of the Femoral Head.股骨头坏死的最新进展
Hip Pelvis. 2023 Sep;35(3):147-156. doi: 10.5371/hp.2023.35.3.147. Epub 2023 Sep 6.
6
Trends in Surgical Treatment of Femoral Head Osteonecrosis in South Korea: An Analysis Using Nationwide Claims Database.韩国股骨头坏死手术治疗趋势：基于全国理赔数据库的分析。
Clin Orthop Surg. 2022 Dec;14(4):500-506. doi: 10.4055/cios22027. Epub 2022 Sep 28.
7
Avascular Necrosis of Femoral Head-Overview and Current State of the Art.股骨头缺血性坏死概述及现状。
Int J Environ Res Public Health. 2022 Jun 15;19(12):7348. doi: 10.3390/ijerph19127348.
8
The Therapeutic Effect of Huo Xue Tong Luo Capsules in Association Research Circulation Osseous (ARCO) Stage II Osteonecrosis of the Femoral Head: A Clinical Study With an Average Follow-up Period of 7.95 Years.活血通络胶囊治疗股骨头缺血性坏死（ARCO）II期的疗效：一项平均随访7.95年的临床研究
Front Pharmacol. 2021 Nov 23;12:773758. doi: 10.3389/fphar.2021.773758. eCollection 2021.
9
Double Trouble-COVID-19 and the Widespread Use of Corticosteroids: Are We Staring at an Osteonecrosis Epidemic?双重麻烦——新冠疫情与皮质类固醇的广泛使用：我们是否正面临骨坏死流行？
Indian J Orthop. 2021 Oct 26;56(2):226-236. doi: 10.1007/s43465-021-00546-8. eCollection 2022 Feb.
10
Insufficient blood supply of fovea capitis femoris, a risk factor of femoral head osteonecrosis.股头圆韧带动脉血供不足，是股骨头坏死的一个危险因素。
J Orthop Surg Res. 2021 Jun 30;16(1):414. doi: 10.1186/s13018-021-02564-6.
本文引用的文献
1
Avascular osteonecrosis after renal transplantation.肾移植后缺血性骨坏死
Transplant Proc. 2007 May;39(4):1036-8. doi: 10.1016/j.transproceed.2007.02.031.
2
Influence of sex and beta2 adrenergic receptor haplotype on resting and terbutaline-stimulated whole body lipolysis.性别和β2肾上腺素能受体单倍型对静息和特布他林刺激的全身脂肪分解的影响。
Metabolism. 2005 Apr;54(4):492-9. doi: 10.1016/j.metabol.2004.11.002.
3
Sexual dimorphism in human lipid metabolism.人类脂质代谢中的性别二态性。
J Nutr. 2005 Apr;135(4):681-6. doi: 10.1093/jn/135.4.681.
4
Spontaneous resolution of osteonecrosis of the femoral head.股骨头坏死的自发缓解
J Bone Joint Surg Am. 2004 Dec;86(12):2594-9. doi: 10.2106/00004623-200412000-00002.
5
Steroid effects on osteogenesis through mesenchymal cell gene expression.类固醇通过间充质细胞基因表达对成骨作用的影响。
Osteoporos Int. 2005 Jan;16(1):101-8. doi: 10.1007/s00198-004-1649-7. Epub 2004 Jun 15.
6
Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures.洛伐他汀通过抑制骨髓间充质细胞培养物中的PPARγ2并增加Cbfa1/Runx2表达来抑制脂肪生成并刺激成骨分化。
Bone. 2003 Oct;33(4):652-9. doi: 10.1016/s8756-3282(03)00239-4.
7
Osteonecrosis of the femoral head after solid organ transplantation: a prospective study.实体器官移植后股骨头缺血性坏死：一项前瞻性研究。
J Bone Joint Surg Am. 2002 Dec;84(12):2145-51. doi: 10.2106/00004623-200212000-00004.
8
Effect of statins on bone mineral density and bone histomorphometry in rodents.他汀类药物对啮齿动物骨密度和骨组织形态计量学的影响。
Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1636-41. doi: 10.1161/hq1001.097781.
9
Statin therapy decreases the risk of osteonecrosis in patients receiving steroids.他汀类药物治疗可降低接受类固醇治疗患者发生骨坏死的风险。
Clin Orthop Relat Res. 2001 May(386):173-8. doi: 10.1097/00003086-200105000-00022.
10
The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis.尼古拉斯·安德里奖。类固醇诱导性骨坏死的发病机制与预防。
Clin Orthop Relat Res. 2000 Jan(370):295-310. doi: 10.1097/00003086-200001000-00030.
Zotero 插件